F. . Xiao, W. . Xiao, X. Li, R. . Li, and K. . Zhao, “Cost-effectiveness analysis of Trastuzumab Deruxtecan as second-line treatment for HER2- positive advanced breast cancer”, Health Decision, vol. 2, no. S1, Jul. 2024.